📊 NVAX Key Takeaways
Is Novavax Inc. (NVAX) a Good Investment?
Novavax exhibits critical structural weaknesses including negative stockholders' equity (-127.8M), severe operating cash burn (-244.6M) despite 440.3M reported net income, and zero revenue/earnings growth, indicating significant earnings quality concerns and sustainability risk. The 27.7% negative FCF margin and balance sheet insolvency suggest the business is destroying fundamental value despite accounting profitability.
Despite reporting strong operating and net margins with positive net income, revenue is flat year over year and cash generation is negative, suggesting weak earnings quality. Negative stockholders’ equity and liabilities exceeding assets present material balance sheet risk, even with adequate liquidity and high interest coverage. Until free cash flow turns sustainably positive and equity recovers, fundamentals skew unfavorably.
Why Buy Novavax Inc. Stock? NVAX Key Strengths
- Strong operating margins (40.3%) and net margins (39.2%) demonstrate operational efficiency and pricing power
- Adequate short-term liquidity with 2.13x current ratio and 240.6M cash reserves provides near-term runway
- Minimal debt burden with only 395K long-term debt reduces refinancing risk
- Strong operating and net margins
- High ROA and interest coverage with minimal long-term debt
- Solid liquidity with current and quick ratios above 2x
NVAX Stock Risks: Novavax Inc. Investment Risks
- Negative stockholders' equity of -127.8M indicates technical balance sheet insolvency
- Severe negative operating cash flow (-244.6M) against positive net income raises critical earnings quality red flags
- Flat revenue and earnings growth (0.0% YoY) in competitive biotech suggests market challenges or lost competitive position
- Massive free cash flow destruction (-310.7M) unsustainable long-term despite liquidity cushion
- Earnings-to-cash disconnect suggests potential one-time gains, working capital deterioration, or operational headwinds
- Negative stockholders’ equity despite reported profits
- Sustained negative operating and free cash flow (earnings quality risk)
- Flat revenue growth (0% YoY) undermines momentum
Key Metrics to Watch
- Operating cash flow normalization - must turn positive to validate earnings quality
- Revenue growth inflection - critical to demonstrate recovery from 0% growth
- Stockholders' equity trajectory - path to positive equity essential for viability
- Free cash flow trend and cash runway depletion rate
- Working capital efficiency and inventory/receivables management
- Free cash flow and operating cash flow trend
- Stockholders’ equity trajectory back to positive
Novavax Inc. (NVAX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.13x current ratio provides a solid financial cushion.
NVAX Profit Margin, ROE & Profitability Analysis
NVAX vs Healthcare Sector: How Novavax Inc. Compares
How Novavax Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Novavax Inc. Stock Overvalued? NVAX Valuation Analysis 2026
Based on fundamental analysis, Novavax Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Novavax Inc. Balance Sheet: NVAX Debt, Cash & Liquidity
NVAX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Novavax Inc.'s revenue has declined by 43% over the 5-year period, indicating business contraction. The most recent EPS of $-5.41 indicates the company is currently unprofitable.
NVAX Revenue Growth, EPS Growth & YoY Performance
NVAX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $70.4M | -$106.5M | $-0.71 |
| Q2 2025 | $239.2M | $14.8M | $0.10 |
| Q1 2025 | $93.9M | -$147.6M | $-1.05 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Novavax Inc. Dividends, Buybacks & Capital Allocation
NVAX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Novavax Inc. (CIK: 0001000694)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NVAX
What is the AI rating for NVAX?
Novavax Inc. (NVAX) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 67% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are NVAX's key strengths?
Claude: Strong operating margins (40.3%) and net margins (39.2%) demonstrate operational efficiency and pricing power. Adequate short-term liquidity with 2.13x current ratio and 240.6M cash reserves provides near-term runway. ChatGPT: Strong operating and net margins. High ROA and interest coverage with minimal long-term debt.
What are the risks of investing in NVAX?
Claude: Negative stockholders' equity of -127.8M indicates technical balance sheet insolvency. Severe negative operating cash flow (-244.6M) against positive net income raises critical earnings quality red flags. ChatGPT: Negative stockholders’ equity despite reported profits. Sustained negative operating and free cash flow (earnings quality risk).
What is NVAX's revenue and growth?
Novavax Inc. reported revenue of $1.1B.
Does NVAX pay dividends?
Novavax Inc. does not currently pay dividends.
Where can I find NVAX SEC filings?
Official SEC filings for Novavax Inc. (CIK: 0001000694) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NVAX's EPS?
Novavax Inc. has a diluted EPS of $2.58.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is NVAX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Novavax Inc. has a SELL rating with 67% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is NVAX stock overvalued or undervalued?
Valuation metrics for NVAX: ROE of N/A (sector avg: 15%), net margin of 39.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy NVAX stock in 2026?
Our dual AI analysis gives Novavax Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is NVAX's free cash flow?
Novavax Inc.'s operating cash flow is $-244.6M, with capital expenditures of $66.0M. FCF margin is -27.7%.
How does NVAX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 39.2% (avg: 12%), ROE N/A (avg: 15%), current ratio 2.13 (avg: 2).